Abstract 2113P
Background
Cisplatin-induced nephrotoxicity (CIN) is a frequent dose-limiting adverse effect, and many nephroprotective strategies have been proposed to prevent its occurrence. Although multiple studies support premedication with magnesium (Mg) and hydration, this intervention has not been widely implemented, as some centers still replace it only after the occurrence of hypomagnesemia. We performed a systematic review and meta-analysis to evaluate the efficacy and effectiveness of Mg supplementation (suppl) prior to cisplatin.
Methods
We systematically searched Pubmed, Embase, and Cochrane databases for randomized clinical trials (RCT) and observational studies assessing prophylactic Mg suppl compared with placebo for patients receiving cisplatin-based chemotherapy. Primary outcomes were acute nephrotoxicity and hypomagnesemia events; secondary outcome included the association of CIN with variations on serum creatinine levels (ΔSCr). We used RevMan 5.1.7 and RStudio for statistical analysis; random-effects models to pool studies; and I2 statistics to assess heterogeneity.
Results
We included 24 studies with 3,803 patients. Nine were RCT and 15 observational cohort studies. We found a significant reduction of risk of CIN (all grades) in patients treated with prophylactic Mg compared to placebo (OR = 0.16; 95%CI 0.11 – 0.24; p<0.001). The pooled analysis including only studies adjusted for confounding variables demonstrated a 67% risk reduction of CIN with Mg suppl (p<0.0001). Mg prophylaxis was effective in both the clinical trial setting (OR = 0.22) and in the real-world data analysis (OR = 0.15). The benefit was seen across all tumor types and combinations of cisplatin-based chemotherapies included in the study. Hypomagnesemia events were significantly less frequent in the intervention group (OR = 0.27; 95%CI 0.16–0.45; p<0.000001). There was no difference regarding doses of Mg administered, and the ΔSCr were not significantly associated with the risk of CIN.
Conclusions
In patients undergoing cisplatin-based chemotherapy, prophylactic Mg suppl significantly reduces the risk of CIN and hypomagnesemia as compared with no prophylaxis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06